Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Diagnostics Ushers In New Era Of Prenatal Testing

Executive Summary

The recent launch of several noninvasive gene-based tests for Down syndrome and other fetal chromosomal abnormalities is poised to upend current prenatal screening practices and potentially usher in a new, multibillion-dollar market opportunity in the process. These new tests employ next-generation gene sequencing, along with advanced, risk-based computer algorithms, to detect and characterize fetal genetic abnormalities using the DNA present in a maternal blood sample. And because they are actually able to “interrogate” the DNA, they represent a huge technological advance over the current standard-of-care for prenatal screening.

Advertisement

Related Content

Noninvasive Prenatal Screening: Battleground In Diagnostics Innovation
Device Trends To Watch In 2013
Washington Roundup, February 2013
Illumina Stakes A Claim In NIPT Market With $450-Million Acquisition Of Verinata
Genomics Enters The Neonatal ICU
Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics
A Hurry-Up-And-Wait Signal For Clinical Whole Genome Sequencing?
In Vitro Diagnostics: The Quest for Growth
Noninvasive Prenatal Diagnostics: How Much Closer to Reality?
Tainted Data Delays Launch Of Sequenom’s Down Syndrome Test

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel